Abstract
In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, estimated the number of actual inpatient lives saved by CCP treatment in the USA based upon CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15% to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, CCP was estimated to have saved between 16,476 and 66,296 lives. The CCP ideal use might have saved as many as 234.869 lives while preventing 1,136,133 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important implications for convalescent plasma used in future infectious disease emergencies.
Significance statement When the COVID-19 pandemic struck in 2020, the population lacked immunity, no validated therapies were available, and mortality was high. COVID-19 convalescent plasma (CCP) was authorized in the United States for treatment of hospitalized patients based on historical evidence of convalescent plasma (CP) efficacy and findings from a nationwide registry suggesting that it reduced mortality. However, this decision was controversial because it was not based on evidence from randomized controlled clinical trials. In this study, we leveraged CCP use and mortality data combined with CCP efficacy data to show that CCP reduced mortality and saved tens of thousands of lives the first year of the pandemic. This provides a powerful basis to consider CP deployment in future infectious disease emergencies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version has been expanded to include a Bayesian analysis of the data that has provided confidence intervals. Two authors have been added: Patrick Johnson and Matthew Buras who carried out the Bayesian analysis.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
